Sanofi: to slash list price of Lantus insulin by 78%
(CercleFinance.com) - Sanofi will reduce the US list price of Lantus (insulin glargine injection) 100 units/ml, Sanofi's most prescribed insulin in the US, by 78%.
The company will also cap the out-of-pocket cost of Lantus at $35 for all patients with health insurance.
These measures, which will take effect on 1 January 2024, will build on decisions already made in June 2022 to reduce the cost of diabetes drugs. The launch of a biosimilar of Lantus at a 60% discount to its list price and the capping of the out-of-pocket expenses for insulin at $35 for all people without insurance, the group said.
Sanofi will also reduce the list price of its short-acting insulin Apidra (insulin glulisine injection) 100 units/ml by 70%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The company will also cap the out-of-pocket cost of Lantus at $35 for all patients with health insurance.
These measures, which will take effect on 1 January 2024, will build on decisions already made in June 2022 to reduce the cost of diabetes drugs. The launch of a biosimilar of Lantus at a 60% discount to its list price and the capping of the out-of-pocket expenses for insulin at $35 for all people without insurance, the group said.
Sanofi will also reduce the list price of its short-acting insulin Apidra (insulin glulisine injection) 100 units/ml by 70%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.